# Differences Between Stavudine and Tenofovir Each Combined With Lamivudine and Efavirenz in SA HIV-infected Patients

> **NCT01601899** · PHASE4 · TERMINATED · sponsor: **University of Witwatersrand, South Africa** · enrollment: 60 (actual)

## Conditions studied

- Mitochondrial Toxicity
- Metabolic Complications

## Interventions

- **DRUG:** Stavudine
- **DRUG:** Stavudine
- **DRUG:** Tenofovir

## Key facts

- **NCT ID:** NCT01601899
- **Lead sponsor:** University of Witwatersrand, South Africa
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-10
- **Primary completion:** 2010-10
- **Final completion:** 2010-12
- **Target enrollment:** 60 (ACTUAL)
- **Why stopped:** DSMB decision to begin closeout process in view of April 2010 SA HAART guideline
- **Last updated:** 2012-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01601899

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01601899, "Differences Between Stavudine and Tenofovir Each Combined With Lamivudine and Efavirenz in SA HIV-infected Patients". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01601899. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*